IL25 and colorectal carcinoma: Studies investigating the role of IL-25 and IL-33 have found conflicting results across the various mouse models that resemble distinct human CRC subtypes, where they may either promote or inhibit tumorigenesis depending on the CRC subtype through different downstream immune mechanisms.